Pyc Therapeutics Ltd has released a press release.
PMS Program Data Supports Progression to Human Trials
Filed with ASX ·
6ix hasn’t read this filing yet.
PYC Therapeutics Limited on 6ix
In the deck
Story so far
Earlier from PYC Therapeutics
- ADOA Program Progressing to Multiple Dose Study
- Board and Management Changes
- Correction to Trading Halt Request
- Change of Managing Director
- ADOA Program - Presentation of Clinical Data at NOSA 2025
Later from PYC Therapeutics
- ADOA Program Initiation of Global Repeat Dose Study
- Sustained Vision Improvement in RP11 Patients
- PKD Clinical Trial - Safety Outcomes in Part A
- Quarterly Activities/Appendix 4C Cash Flow Report
- Trading Halt
Follow PYC Therapeutics into a list and get an email when it puts out news.
Follow PYC Therapeutics